New drug cocktail shows promise for Tough-to-Treat lymphomas

This phase 2 trial tests whether adding polatuzumab vedotin to standard chemotherapy can improve outcomes for people with aggressive B-cell lymphomas, including double-hit and triple-hit types. Only 8 participants were enrolled, and the study focuses on safety and how many achieve complete remission. While early results may point to a better treatment option, the small size and lack of a comparison group mean we need larger studies to confirm any benefit.